JNJames Craig Nelson

James Craig Nelson

*This is an algorithmically generated author record based on publicly available information.

James Craig Nelson has a total of 69 co-authors. Here are the top co-authors by number of shared publications:

  • Kevin Delucchi

    University of California, Department of Psychiatry and Langley Porter Psychiatric Institute, San Francisco, CA

    5 shared publications
  • Robert M. Berman

    Yale School of Medicine, New Haven, CT, USA; Bristol-Myers Squibb, Wallingford, CT, USA

    5 shared publications
  • Lon S. Schneider

    From the Department of Psychiatry, University of California San Francisco; and the Departments of Psychiatry and Behavioral Sciences and of Neurology, Keck School of Medicine, and the Leonard Davis School of Gerontology, University of Southern California, Los Angeles

    4 shared publications
  • James M. Eudicone

    Global Biometric Sciences Department, Bristol-Myers Squibb, Plainsboro, New Jersey, USA

    3 shared publications
  • Ronald N. Marcus

    NS Global Clinical Research, Bristol-Myers Squibb, Wallingford, Connecticut, USA

    3 shared publications
  • Ross A. Baker

    CNS Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey, USA

    3 shared publications

Latest Publications

  • Open Access

    Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: A pooled analysis

    by Thomas D. Stewart, Ainslie Hatch, Kimberly Largay, John J. Sheehan, Sabrina V. Marler, Robert M. Berman, J. Craig Nelson


  • Open Access

    Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy

    by J. Craig Nelson, Zia Rahman, Kimberly K. Laubmeier, James M. Eudicone, Robert D. McQuade, Robert M. Berman, Ronald N. Marcus, Ross A. Baker, John J. Sheehan

    Introduction: Efficacy of depression treatments, including adjunctive antipsychotic treatment, has not been explored for patients with worsening symptoms after antidepressant therapy (ADT).Methods: This post-hoc analysis utilized pooled data from 3 similarly designed, randomized, double-blind, placebo-controlled trials that assessed the efficacy, safety, and tolerability of adjunctive aripiprazole in patients with major depressive disorder with inadequate response to ADT. The studies had 2 phases: an 8-week prospective ADT phase and 6-week adjunctive (aripiprazole or placebo) treatment phase. This analysis focused on patients whose symptoms worsened during the prospective 8-week ADT phase (worsening defined as >0% increase in Montgomery–Åsberg Depressive Rating Scale [MADRS] Total score). During the 6-week, double-blind, adjunctive phase, response was defined as ≥50% reduction in MADRS Total score and remission as ≥50% reduction in MADRS Total score and MADRS score ≤10.Results: Of 1065 patients who failed to achieve a response during the prospective phase, 160 exhibited worsening of symptoms (ADT-Worseners), and 905 exhibited no change/reduction in MADRS scores (ADT-Non-worseners). Response rates for ADT-Worseners at endpoint were 36.6% (adjunctive aripiprazole) and 22.5% (placebo). Similarly, response rates at endpoint for ADT-Non-worseners were 37.5% (adjunctive aripiprazole) and 22.5% (placebo). Remission rates at endpoint for ADT-Worseners were 25.4% (adjunctive aripiprazole) and 12.4% (placebo). For ADT-Non-worseners, remission rates were 29.9% (adjunctive aripiprazole) and 17.4% (placebo).Conclusion: These results suggest that adjunctive aripiprazole is an effective intervention for patients whose symptoms worsen during antidepressant monotherapy. The results challenge the view that benefits of adjunctive therapy with aripiprazole are limited to partial responders to ADT.


  • Moderators of Outcome in Late-Life Depression: A Patient-Level Meta-Analysis

    by J. Craig Nelson, Kevin L. Delucchi, Lon S. Schneider

    The authors sought to identify factors that moderate outcome in late-life major depression and that identify patients for whom antidepressants have clinically meaningful effects. A previous systematic review identified 10 placebo-controlled trials of second-generation antidepressants in outpatients with major depressive disorder who were age 60 or older. For the present study, the authors obtained from the sponsors of the 10 trials individual patient data, including age, sex, duration of illness (current age minus age at onset), course (single episode or recurrent depression), baseline depression severity, treatment assignment, and outcomes. Logistic regression models were estimated and tested to examine the association of potential moderator variables with treatment response and the treatment group-response interaction. All moderator variables were collected and documented for seven of the 10 trials (N=2,283). Univariate and multivariate analyses were restricted to these seven trials. Illness duration was the only variable significantly associated with drug-placebo differences in the multivariate model. In patients with an illness duration >10 years, baseline depression severity was also significantly associated with drug-placebo differences. In those with an illness duration >10 years and a Hamilton Depression Rating Scale score ≥21, the drug-placebo difference in response rates was relatively robust (number needed to treat=4). In the remaining patients, the drug-placebo difference in response rates was small (46.3% compared with 41.5%). Older patients with a long illness duration and moderate to severe depression appear to benefit from antidepressants as compared with placebo. Antidepressants do not appear to be effective for older patients with short illness duration.


  • Foreword

    by J. Craig Nelson


  • Baseline patient characteristics associated with placebo remission and their impact on remission with duloxetine and selected SSRI antidepressants

    by J. Craig Nelson, Qianyi Zhang, Katarina Kelin, Elias Eriksson, Walter Deberdt, Michael Berk

    OBJECTIVE: We examined whether identification of patients with placebo-remitter characteristics and placebo-nonremitter characteristics enhances the ability to identify drug-placebo treatment differences and, perhaps, differences between agents in major depressive disorder (MDD). We hypothesized: 1) that drug-placebo differences in remission rates would be greater for both duloxetine and selective serotonin reuptake inhibitors (SSRIs) among placebo nonremitters than placebo remitters and: 2) that the difference between active treatments would also be greater in placebo nonremitters than placebo remitters. DATA AND METHODS: Data were obtained from seven randomized, parallel, double-blind MDD studies which compared the effects of duloxetine (N = 795), placebo (N = 510), and SSRIs (N = 551). The 17-item Hamilton depression rating scale (HAMD) was used to assess depression severity. The classification of participants as having placebo-remitter or placebo-nonremitter characteristics was based on age, duration of current MDD episode, HAMD anxiety score, and HAMD core score. Odds ratios (ORs) for remission comparing active treatment and placebo were obtained from logistic regression models. Tests of homogeneity were used for between-group comparisons. RESULTS: For placebo nonremitters, both duloxetine (OR = 3.52 [95% CI: 2.21, 5.62; P < 0.0001]) and SSRIs (OR = 2.38 [95% CI: 1.45, 3.89; P = 0.0006]) showed significantly higher remission rates compared to placebo. Drug-placebo differences in remission were significantly greater for placebo nonremitters than for placebo remitters for both duloxetine (P = 0.02) and SSRIs (P = 0.049). For placebo remitters, remission with duloxetine (OR = 1.83 [95% CI: 1.35, 2.47; P = 0.0001]), but not the SSRIs selected for this study (OR = 1.31 [95% CI: 0.93, 1.84; P = 0.12]), was significantly greater than placebo. Contrary to expectation, the advantage of duloxetine over the SSRIs was not greater in placebo nonremitters. However, the fact that our analysis required patient-level data limited the number of agents studied, compromising generalization. CONCLUSIONS: Our study suggests that drug-placebo differences in remission rates will be greater in subjects with placebo-nonremitter than with placebo-remitter characteristics


  • Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy

    by James Craig Nelson, Michael E. Thase, Elizabeth E. Bellocchio, Linda M. Rollin, James M. Eudicone, Robert D. McQuade, Ronald N. Marcus, Robert M. Berman, Ross A. Baker

    To evaluate the efficacy of adjunctive aripiprazole in patients with minimal response to prior antidepressant therapy (ADT). Pooled data from three randomized, double-blind, placebo-controlled studies assessing the efficacy of adjunctive aripiprazole to ADT in patients with major depressive disorder who had a minimal response [<25% reduction on the Montgomery-Asberg Depression Rating Scale (MADRS)] to an 8-week prospective ADT. During the 6-week, double-blind adjunctive phase, response was defined as at least 50% reduction in the MADRS score and remission as at least 50% reduction in MADRS score and a MADRS score <= 10. Rates were examined using analysis of covariance and Cochran-Mantel-Haenszel tests. Kaplan-Meier curves were used to calculate time to response and remission. Of 1038 patients, 72% (n=746) exhibited a minimal response to ADT (ADT minimal responder). Time to response and remission were significantly shorter for ADT minimal responders receiving aripiprazole + ADT versus adjunctive placebo + ADT. ADT minimal responders on aripiprazole + ADT showed significantly greater improvements in MADRS score at endpoint compared with minimal responders on placebo + ADT (-10.3 vs. -6.5, P < 0.0001). In addition, ADT minimal responders exhibited significantly higher response rates with aripiprazole + ADT than placebo + ADT (36 vs. 19%, respectively, P < 0.0001) and higher remission rates (24 vs. 12%, respectively, P < 0.0001). The numbers needed to treat with aripiprazole + ADT were six for response and eight for remission. Aripiprazole augmentation had a rapid and clinically meaningful effect in ADT minimal responders. Int Clin Psychopharmacol 27: 125-133 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.